Intellectual Property Landscape Assessment

Searches were conducted through international and domestic patent databases using the search terms "psilocybin" and "depression" in patent claims. 271 results were returned and what follows is an analysis of claims described in existing documents that have priority dates that predate the abovementioned priority document [document number _____]. The search was completed on September 15, 2023.

This document is split into three parts:

- 1) Granted, active U.S. patents
- 2) Pending U.S. patent applications and additional patent documents relevant to the proposed invention
- 3) Non-patent references pertinent to the described technology that exists in the public domain

Also included in this package are all priority documents of patent applications listed in above section 2.

1. Granted, Active Patents

The following table documents all active patents relevant to the portion of the IP landscape the proposed invention seeks to occupy.

The "relevant claims" column contains text highlighted in **green** if it is directly relevant to and in the scope of the proposed invention, and **red** if it qualifies the claim and lends credibility to its inapplicability to the presently proposed invention.

Patent Number	Legal Status	Family Members	Title	Assignee	Relevant claims	International national stage applications filed? (Y/N)	Relevant litigation (Y/N)	Relevance (Y/N)
US10519175	Active	<u>U.S. Patents</u> 10947257, 10954259, 11149044, 11180517, 11447510, 11505564, 11629159 <u>U.S. Applications</u> 17/990,979, 18/135,265	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use	Compass Pathfinder Limited	 A method of treating drug resistant depression comprising orally administering to a subject in need thereof a therapeutically effective amount of an oral dosage form, wherein, the oral dosage form comprises: crystalline psilocybin in the form Polymorph A characterized by peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, 17.5, and 19.7°20±0.1°20, wherein the crystalline psilocybin has a chemical purity of greater than 97% by HPLC, and no single impurity of greater than 97% by HPLC, and no single impurity of greater than 1%; and silicified microcrystalline cellulose. The method of claim 1, wherein the oral dosage form comprises 1 mg to 40 mg of crystalline psilocybin in the form Polymorph A. The method of claim 2, wherein the oral dosage form comprises 5 mg of crystalline psilocybin in the form Polymorph A. The method of claim 2, wherein the oral dosage form comprises 10 mg of crystalline psilocybin in the form Polymorph A. The method of claim 2, wherein the oral dosage form comprises 5 mg of crystalline psilocybin in the form Polymorph A. The method of claim 2, wherein the oral dosage form comprises 10 mg of crystalline psilocybin in the form Polymorph A. The method of claim 2, wherein the oral dosage form comprises 25 mg of crystalline psilocybin in the form Polymorph A. 	Y	Ν	N
US10947257	Active	<u>U.S. Patents</u> 10519175,	Preparation of psilocybin, different	Compass Pathfinder Limited	1. An oral dosage form comprising: a therapeutically effective amount of crystalline psilocybin in the form Polymorph A characterized by peaks in an	Y	Y (PGR - unsuccessful	N

		10954259, 11149044, 11180517, 11447510, 11505564, 11629159 <u>U.S. Applications</u> 18/135,265	polymorphic forms, intermediates, formulations and their use		 XRPD diffractogram at 11.5, 12.0, 14.5, 17.5, and 19.7°20±0.1°20, wherein the crystalline psilocybin has a chemical purity of greater than 97% by HPLC, and no single impurity of greater than 1%; and silicified microcrystalline cellulose. 2. The oral dosage form of claim 1 comprising about 1 mg to 40 mg of crystalline psilocybin in the form Polymorph A. 3. The oral dosage form of claim 2 comprising about 5 mg of crystalline psilocybin in the form Polymorph A. 4. The oral dosage form of claim 2 comprising about 10 mg of crystalline psilocybin in the form Polymorph A. 5. The oral dosage form of claim 2 comprising about 25 mg of crystalline psilocybin in the form Polymorph A. 5. The oral dosage form of claim 2 comprising about 25 mg of crystalline psilocybin in the form Polymorph A. 5. The oral dosage form of claim 2 comprising about 25 mg of crystalline psilocybin in the form Polymorph A. 		challenge to patentability)	
US10954259	Active	<u>U.S. Patents</u> 10519175, 10947257, 11149044, 11180517, 11447510, 11505564, 11629159 <u>U.S. Applications</u> 18/135,265	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use	Compass Pathfinder Limited	 16. A method of treating major depressive disorder, the method comprising: administering a therapeutically effective amount of crystalline Polymorph A of psilocybin to a patient in need thereof, wherein the Polymorph A is characterized by X-ray powder diffraction (XRPD) peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1 °20, and wherein the psilocybin has a chemical purity of greater than 97% and no single impurity of greater than 1% as determined by HPLC analysis. 17. The method of claim 16, wherein about 5 mg of the crystalline Polymorph A of psilocybin is administered. 18. The method of claim 16, wherein about 10 mg of the crystalline Polymorph A of psilocybin is administered. 19. The method of claim 16, wherein about 25 mg of the crystalline Polymorph A of psilocybin is administered. 20. The method of claim 16, wherein the crystalline Polymorph A of psilocybin is administered. 	Ŷ	Y (PGR - unsuccessful challenge to patentability)	Ν
US11149044	Active	<u>U.S. Patents</u> 10519175, 10947257, 10954259, 11180517,	Preparation of psilocybin, different polymorphic forms,	Compass Pathfinder Limited	15. A method of treating major depressive disorder, the method comprising: administering a therapeutically effective amount of crystalline Hydrate A of psilocybin to a patient in need thereof,	Ŷ	N	N

		11447510, 11505564, 11629159 <u>U.S. Applications</u> 18/135,265	intermediates, formulations and their use		 wherein the crystalline Hydrate A is characterized by X-ray powder diffraction (XRPD) peaks at 8.9±0.1, 13.8±0.1, 19.4±0.1, 23.1±0.1 and 23.5±0.1°20, and wherein the psilocybin has a chemical purity of greater than 97% and no single impurity of greater than 1% as determined by HPLC analysis. 16. The method of claim 15, wherein about 5 mg of the crystalline Hydrate A of psilocybin is administered. 17. The method of claim 15, wherein about 10 mg of the crystalline Hydrate A of psilocybin is administered. 18. The method of claim 15, wherein about 25 mg of the crystalline Hydrate A of psilocybin is administered. 19. The method of claim 15, wherein about 25 mg of the crystalline Hydrate A of psilocybin is administered. 19. The method of claim 15, wherein the crystalline Hydrate A of psilocybin is administered. 			
US11180517	Active	<u>U.S. Patents</u> 10519175, 10947257, 10954259, 11149044, 11447510, 11505564, 11629159 <u>U.S. Applications</u> 18/135,265	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use	Compass Pathfinder Limited	 13. A method of treating treatment resistant depression, the method comprising administering a therapeutically effective amount of psilocybin to a patient in need thereof, wherein the psilocybin comprises a crystalline Polymorph A of psilocybin characterized by X-ray powder diffraction (XRPD) peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1°20, and wherein the psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis. 14. The method of claim 13, wherein about 1 mg to about 40 mg of psilocybin is administered. 15. The method of claim 13, wherein about 10 mg to about 30 mg of psilocybin is administered. 16. The method of claim 13, wherein about 1 mg of psilocybin is administered. 17. The method of claim 13, wherein about 5 mg of psilocybin is administered. 18. The method of claim 13, wherein about 25 mg of psilocybin is administered. 19. The method of claim 13, wherein about 25 mg of psilocybin is administered. 20. The method of claim 13, wherein the psilocybin is orally administered. 	Ŷ	N	Ν

US11447510	Active	U.S. Patents 10519175, 10947257, 10954259, 11149044, 11180517, 11505564, 11629159 U.S. Applications 17/990,979, 18/135,265	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use	Compass Pathfinder Limited	 14. A method of treating treatment resistant depression, the method comprising administering a therapeutically effective amount of psilocybin to a patient in need thereof, wherein the psilocybin comprises a crystalline Hydrate A of psilocybin characterized by X-ray powder diffraction (XRPD) peaks at 8.9±0.1, 13.8±0.1, 19.4±0.1, 23.1±0.1 and 23.5±0.1°20, and wherein the psilocybin has a chemical purity of greater than 97% and no single impurity of greater than 1% as determined by HPLC analysis. 15. The method of claim 14, wherein about 1 mg to about 40 mg of psilocybin is administered. 16. The method of claim 14, wherein about 10 mg to about 30 mg of psilocybin is administered. 17. The method of claim 14, wherein about 1 mg of psilocybin is administered. 18. The method of claim 14, wherein about 5 mg of psilocybin is administered. 19. The method of claim 14, wherein about 25 mg of psilocybin is administered. 20. The method of claim 14, wherein about 25 mg of psilocybin is administered. 21. The method of claim 14, wherein about 25 mg of psilocybin is administered. 	Y	Ν	Ν
US11505564	Active	<u>U.S. Patents</u> 10519175, 10947257, 10954259, 11149044, 11180517, 11447510, 11629159 <u>U.S. Applications</u> 17/990,979, 18/135,265	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use	Compass Pathfinder Limited	N/A	Y	Ν	Ν
US10729706	Active	U.S. Applications 17/880,134 WIPO Applciations PCT/NL2018/050037	Psilocybin and/or psilocin in combination with	Procare Beheer B.V.	1. A method for preventing or treating a psychological disorder in a patient, comprising: administrating psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene, wherein the at least one cannabinoid and/or at least one terpene is	Y	N	Ν

			cannabinoids and/or terpenes		 administered separately, sequentially or simultaneously to the psilocybin and/or psilocin. 2. The method of claim 1, wherein the psychological disorder is chosen from depression, psychotic disorder, schizophrenia, schizophreniform disorder (acute schizophrenic episode); schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis); bipolar II disorder; major depressive disorder with psychotic feature (psychotic depression); delusional disorders (paranoia); Shared Psychotic Disorder (Shared paranoia disorder); Brief Psychotic disorder not otherwise specified (Unspecified Psychotic disorder not otherwise specified (Unspecified Psychotic); paranoid personality disorder, anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome, premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS). 			
US11471450	Active	<u>U.S. Patents</u> 11590120 <u>U.S. Applications</u> 16/211,281 15/494,503 17/942,763 <u>Priority documents</u> 62/365,982 (02/23 /2016)	Psilocybin compositions	Turtle Bear Holdings LLC	 A composition comprising: 0.1 mg to 10 mg of psilocybin or psilocin; an extract of Hericium erinaceus comprising 50 mg to 200 mg of erinacines or hericenones; and 199 mg of one or more medicinal mushroom species of Inonotus mycelia, fruitbodies, mycelial extracts, fruitbody extracts, or combinations thereof. A composition comprising: 0.1 to 10 mg of psilocybin or psilocin; an extract of Hericium erinaceus comprising 50 mg to 200 mg of erinacines or hericenones; 199 mg of one or more medicinal mushroom species of Inonotus mycelia, fruitbodies, mycelial extracts, fruitbody extracts or combinations thereof, and niacin. 	Ν	N	Ν
US11590120	Active	<u>U.S. Patents</u> 11471450 11701348 <u>U.S. Applications</u> 15/494,503 17/669,845 18/354,403 16/992,631 16/951,012 17/308,869 18/114,381 17/942,763 17/480,789 Priority documents	Psilocybin compositions	Turtle Bear Holdings LLC	 A pharmaceutical formulation comprising of: 0.1 mg to 10 mg of psilocybin or psilocin; and an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones. A pharmaceutical formulation comprising of: 0.1 mg to 10 mg of psilocybin or psilocin; an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; and 1 mg to 50 mg of niacin. A pharmaceutical formulation comprising of: 0.1 mg to 10 mg psilocybin or psilocin; and 1 mg to 50 mg of niacin. A pharmaceutical dosage comprising a tablet, capsule, elixir, or suspension comprising of: 0.1 mg to 10 mg psilocybin or psilocin; an extract of Hericium erinaceus 	Ν	N	Ν

		62/365,982 (02/23/2016)			comprising 0.1 mg to 200 mg of erinacines or hericenones; and 1 mg to 50 mg of niacin.			
US11701348	Active	U.S. Patents 11590120 U.S. Applications 18/354,403 16/211,281 15/494,503 Priority documents 62/365,982 (02/23/2016)	Psilocybin compositions	Turtle Bear Holdings LLC	 A method for reducing symptoms of depression in a subject in need thereof comprising: administering a dosage form comprising; Ing to 10 mg of psilocybin or psilocin; an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; and I mg to 50 mg of niacin; sufficient to reduce the symptoms of depression in the subject The method of claim 1, wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin. The method of claim 1, wherein the dosage form is a capsule. A method for reducing symptoms of depression in a subject in need thereof comprising: administering a dosage form comprising: Ing to 10 mg of psilocybin or psilocin; and an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; sufficient to reduce the symptoms of depression in the subject. The method of claim 8, wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin; and an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; sufficient to reduce the symptoms of depression in the subject. The method of claim 8, wherein the dosage form comprises 0.1 mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10 mg; or 1 mg to 10 mg of psilocybin or psilocin. The method of claim 8, wherein the dosage form is a capsule. A method for reducing symptoms of depression in a subject in need thereof comprising: administering a dosage form comprising: administering a dosage form comprising: Ing to 10 mg of psilocybin or psilocin; mg to 50 mg of niacin; sufficient to reduce the symptoms of depression in the subject. The method of claim 16, wherein the dosage form comprises 0.1 mg to 10 mg of psilocybin or psilocin; mg to 50 mg of niacin; sufficient to red	Ν	Ν	Ν

2. Additional Patent Documents

The following table documents relevant patent documents (active applications, expired patents, etc.) that are relevant to the portion of the IP landscape the proposed invention seeks to occupy.

The "published patent doc #" column is color coded according to Porta Sophia's opinion regarding the likelihood of the specific document's claims being granted patent rights as those claims are described at the point this landscape analysis was generated. **Red** denotes that it is unlikely that the claims will be granted in their current state, yellow indicates that there is some chance that some claims may be granted as they stand, and green indicates that it is likely that the claims will be granted in their current form.

The "relevant claims" column contains text highlighted in **green** if it is directly relevant to and in the scope of the proposed invention, and **red** if it qualifies the claim and lends credibility to its inapplicability to the presently proposed invention.

Published Patent Doc #	Legal Status	Family Members	Title	Assignee	Relevant claims	International national stage applications filed? (Y/N)	Relevance (Y/N)	Third party intervention filed (Y/N)
US20210251976	Pending	<u>U.S. Patents</u> 11590120 <u>U.S. Applications</u> 16/951,012 16/211,281 15/494,503 <u>Priority documents:</u> U.S. 62/937,536 (11/19/2019) U.S. 63/007,482 (04/09/2020) U.S. 62/365,982 (07/23/2016)	TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH	Turtle Bear Holdings LLC	 A method of treating or improving a mental health disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising from about 1 mg to about 10 mg of one or more of psilocybin, psilocin, esters, or salts thereof; or an equivalent amount of a psilocybin containing mushroom; and one or more pharmaceutically acceptable excipients. The method of claim 1, wherein the mental health disorder is a psychiatric and mood disorder comprising depression, anxiety, major depressive disorder, treatment resistant depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, 	Ν	Y	Ν

					panic disorder, post-traumatic stress disorder, or a combination thereof.			
US20230000885	Pending	U.S. Applications 17/634,729 WIPO applications: PCT/US2020/04614 9 <u>Priority documents:</u> U.S. 62/886,090 (13 August 2019)	Methods of Treating Psychological and Brain Disorders	University of Maryland, Baltimore	 25. A method for treating depression or symptoms thereof in a subject in need thereof, comprising: (a) administering to the subject a serotonin receptor 2A antagonist; and (b) administering to the subject a serotonin agonist selected from psilocybin, psilocin, LSD and lisurgide; wherein the serotonin agonist is administered separately, sequentially or simultaneously with the serotonin receptor 2A antagonist. 30. The method of claim 25, wherein the serotonin agonist is psilocybin or psilocin. 31. The method of claim 30, wherein the serotonin agonist is psilocybin. 39. The method of claim 25, wherein the depression is major depression, psychotic depression, treatment-resistant depression (TRD), or postpartum depression. 	Y	Ν	Y
US20230023092	Pending	WIPO applications: PTC/IB2020/05368 PTC/IB2020/05368 8 Priority documents: U.S. 62/946,159 U.S. 62/946,159 (12/10/2019) U.S. 62/893,611 (08/29/2019) U.S. 62/893,110 (08/28/2019) U.S. 62/835,485 (04/17/2019) U.S. 62/835,484 (04/17/2019) U.S. 62/835,481 (04/17/2019) U.S. 62/835,480 (04/17/2019) U.S. 62/835,479 (04/17/2019) U.S. 62/835,479 (04/17/2019) U.S. 62/835,479 (04/17/2019) U.S. 62/835,478	TREATMENT OF DEPRESSION AND OTHER VARIOUS DISORDERS WITH PSILOCYBIN	Compass Pathfinder Limited	 A method of treating depression in a subject in need thereof, the method comprising administering an effective amount of crystalline psilocybin to the subject, wherein the crystalline psilocybin is characterized by XRPD peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1° wherein the crystalline psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis, and wherein the subject has bipolar disorder, or a depressive disorder due to a medical condition. The method of claim 1, wherein at least one sign or symptom of depression selected from depressed mood, diminished interest in activities, weight loss or gain, decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to concentrate or indecisiveness, or suicidal ideation or behavior is reduced. 	Y	N	N

		(04/17/2019) U.S. 62/835,477 (04/17/2019) U.S. 62/835,476 (04/17/2019) U.S. 62/835,474 (04/17/2019) U.S. 62/835,472 (04/17/2019) U.S. 62/835,465 (04/17/2019) U.S. 62/835,464 (04/17/2019) U.S. 62/835,458 (04/17/2019) U.S. 62/835,458 (04/17/2019) U.S. 62/835,459 (04/17/2019) U.S. 62/835,449 (104/17/2019)			 56. The method claim 1, wherein the crystalline psilocybin is administered in an oral dosage form. 60. The method of claim 1, wherein the effective amount of crystalline psilocybin is in the range of about 0.1 mg to about 100 mg. 61. The method of claim 60, wherein the effective amount of crystalline psilocybin is about 1 mg. 62. The method of claim 60, wherein the effective amount of crystalline psilocybin is about 1 mg. 63. The method of claim 60, wherein the effective amount of crystalline psilocybin is about 10 mg. 63. The method of claim 60, wherein the effective amount of crystalline psilocybin is about 25 mg. 			
US20230151036	Pending	WIPO applications: PCT/US2022/07975 2 Priority documents: U.S. 63/278,943 (11/12/2021) U.S. 63/279,005 (11/12/2021) U.S. 63/280,294 (11/17/2021) U.S. 63/280,300 (11/17/2021) U.S. 63/280,300 (11/17/2021) U.S. 63/280,300 (11/17/2021) U.S. 63/285,050 (12/01/2021) U.S. 63/300,957 (01/19/2022) U.S. 63/300,961 (01/19/2022) U.S. 63/305,643 (02/01/2022) U.S. 63/310,984 (02/16/2022) U.S. 63/310,987 (02/16/2022) U.S. 63/311,878	PSILOCYBIN AND O- ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF	Terran Biosciences Inc.	1. A crystalline form of psilocybin.HCl (Form A) that is characterized as having: an X-ray powder diffraction (XRPD) diffractogram with characteristic peaks at $6.1\pm0.2^{\circ}$ 2-Theta, 9.9±0.2° 2-Theta, and $14.3\pm0.2^{\circ}$ 2-Theta, optionally further comprising peaks at $18.0\pm0.2^{\circ}$ 2-Theta and $19.8\pm0.2^{\circ}$ 2-Theta, as measured with Cu Kα radiation, or an XRPD diffractogram with characteristic peaks at $6.0\pm0.2^{\circ}$ 2-Theta, $9.9\pm0.2^{\circ}$ 2-Theta, and $14.6\pm0.2^{\circ}$ 2-Theta, optionally with further characteristic peaks at $18.0\pm0.2^{\circ}$ 2-Theta and $19.7\pm0.2^{\circ}$ 2-Theta, as measured with Cu Kα radiation, or an XRPD diffractogram with characteristic peaks at $6.1\pm0.2^{\circ}$ 2-Theta, $9.9\pm0.2^{\circ}$ 2-Theta, and $14.3\pm0.2^{\circ}$ 2-Theta, optionally further comprising peaks at $16.9\pm0.2^{\circ}$ 2-Theta and $18.1\pm0.2^{\circ}$ 2-Theta, as measured with Cu Kα radiation. 5. A crystalline form of psilocybin.HCl (Form A) that is characterized as having: an X-ray powder diffraction (XRPD) diffractogram with characteristic peaks at $6.1\pm0.2^{\circ}$ 2-Theta, optionally further	Ν	Ν	Ν

(02/18/2022)		comprising peaks at 18 0+0.2° 2. Theta and		
(02/10/2022)		10.9 × 0.28 2. These are used sound and		
0.3. 65/313,901		19.8 ± 0.2 2-Theta, as measured with Cu Ku		
(03/02/2022)		radiation, or		
0.8.63/316,952		an XRPD diffractogram with characteristic		
(03/04/2022)		peaks at $6.0\pm0.2^{\circ}$ 2-Theta, $9.9\pm0.2^{\circ}$ 2-Theta,		
U.S. 63/319,746		and 14.6±0.2° 2-Theta, optionally with further		
(03/14/2022)		characteristic peaks at 18.0±0.2° 2-Theta and		
U.S. 63/321,593		19.7±0.2° 2-Theta, as measured with Cu Kα		
(03/18/2022)		radiation, or		
U.S. 63/324,878		an XRPD diffractogram with characteristic		
(03/29/2022)		peaks at 6.1+0.2° 2-Theta, 9.9+0.2° 2-Theta.		
U.S. 63/326.364		and 14 3+0 2° 2-Theta optionally further		
(04/01/2022)		comprising peaks at 16.9+0.2° 2-Theta and		
US 63/326 421		$18 1\pm0.2^{\circ} 2$ Theta as measured with Cu Ka		
(04/01/2022)		rediction: and		
(04/01/2022)		a differential scenning colorimetry (DSC)		
0.5. 05/520,522		a differential scanning calorimetry (DSC)		
(04/01/2022)		thermogram with an endotherm at about		
U.S. 63/326,/13		189.3° C. when measured at a heating rate of		
(04/01/2022)		10° C./min, or a thermogravimetric analysis		
U.S. 63/357,378		(TGA) spectrum showing a 0.2% loss up to		
(06/30/2022)		130° C., and a 1.3% loss from 130° C. to 195°		
U.S. 63/357,512		C., or both.		
(06/30/2022)				
		9. A crystalline form of psilocybin.HCl that		
		is characterized as having unit cell		
		parameters substantially equal to the		
		following at 100 K:		
		crystal system, space group Monoclinic,		
		P21/n data collection temperature (K) 150 a		
		$(\text{\AA}) \ 8 \ 4691 \ (4) \ \text{b} \ (\text{\AA}) \ 29 \ 5481 \ (14) \ \text{c} \ (\text{\AA})$		
		115761(5) B (°) 1026579 (14) volume		
		(3) 28265 (2) 7 4		
		(A3) 2020.3 (2) 2 4.		
		10 A anastalling form of poilogybin UCI that		
		is a an arrestal of neilearbin and		
		is a co-crystal of pshocybin and		
		stoicniometry of two moles of psilocybin to		
		one mole of hydrochloric acid and is		
		characterized as having unit cell		
		parameters substantially equal to the		
		following at 100 K:		
		crystal system, space group Monoclinic,		
		P21/n data collection temperature (K) 150 a		
		(A) 8.4691 (4) b (Å) 29.5481 (14) c (Å)		
		11.5761 (5) β (°) 102.6579 (14) volume		
		(Å ³) 2826.5 (2) Z 4.		
		12. A method of treating a neurological		
		disorder, a psychiatric disorder, or both in		
		a human subject comprising administering		

		to the human subject in need thereof an		
		amount of the crystalline form of		
		nsilocybin HCl according to claim 1 that is		
		agging last to shout 10 mg to shout 50 mg of		
		equivalent to about 10 mg to about 50 mg of		
		psilocybin, wherein the neurological		
		disorder, psychiatric disorder, or both		
		comprises depression, addiction, substance		
		use disorder anxiety post-traumatic stress		
		disender, anxiety, post-traumate stress		
		disorder, suicidal ideation, bipolar disorder,		
		schizophrenia, stroke, traumatic brain injury,		
		or a combination thereof.		
		17 A method of treating a neurological		
		disorder a neurobiotria disorder or both in		
		disorder, a psychiatric disorder, or both in		
		a human subject comprising administering		
		to the human subject in need thereof an		
		amount of the crystalline form of		
		nsilocybin.HCl according to claim 5 that is		
		aquivalent to about 10 mg to about 50 mg of		
		equivalent to about 10 mg to about 50 mg of		
		pshocybin, wherein the neurological		
		disorder, psychiatric disorder, or both		
		comprises depression, addiction, substance		
		use disorder, anxiety, post-traumatic stress		
		disorder suicidal ideation bipolar disorder		
		schizophrania stroke traumatic brain injury		
		semzophiema, suoke, traumate brain injury,		
		or a combination thereof.		
		18. The method of claim 17, wherein the		
		neurological disorder, psychiatric disorder,		
		or both comprises treatment resistant		
		depression		
		depression.		
		20. The method of claim 17 , wherein the		
		method comprises orally administering to		
		the human subject in need thereof an		
		amount of the crystalline form of		
		nsilocybin HCl according to claim 5 that is		
		ponocy official according to train 5 that is		
		equivalent to about 10 mg, about 15 mg,		
		about 20 mg, about 25 mg, about 30 mg,		
		about 35 mg, about 40 mg, about 45 mg, or		
		about 50 mg of psilocybin.		
		22. A method of treating a neurological		
		disorder a nevchiatric disorder or both in		
		a human subject comprising a desired to the		
		a numan subject comprising administering		
		to the human subject in need thereof an		
		amount of the crystalline form of		
		psilocybin.HCl according to claim 9 that is		
		equivalent to about 10 mg to about 50 mg of		
		nsilocyhin wherein the neurological		
		pshoeyoni, wherein the neurological		

					 disorder, psychiatric disorder, or both comprises depression, addiction, substance use disorder, anxiety, post-traumatic stress disorder, suicidal ideation, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or a combination thereof. 23. The method of claim 22, wherein the neurological disorder, psychiatric disorder, or both comprises treatment resistant depression. 25. The method of claim 22, wherein the method comprises orally administering to the human subject in need thereof an amount of the crystalline form of psilocybin.HCl according to claim 9 that is equivalent to about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, or about 50 mg of psilocybin. 26. A pharmaceutical composition, comprising the crystalline form of psilocybin.HCl according to claim 10, and a pharmaceutically acceptable excipient. 27. A method of treating a neurological disorder, a psychiatric disorder, or both in a human subject in need thereof an amount of the crystalline form of psilocybin.HCl according to claim 10 that is equivalent to about 10 mg to about 50 mg of psilocybin.HCl according to claim 10 that is equivalent to about 10 mg to about 50 mg of psilocybin, wherein the neurological disorder, psychiatric disorder, or both comprises depression, addiction, substance use disorder, nixety, post-traumatic stress disorder, suicidal ideation, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or a combination thereof. 28. The method of claim 27, wherein the neurological disorder, psychiatric disorder, or both comprises treatment resistant 			
US20220169668	Pending	WIPO applications:	METHODS OF	Compass	depression. 1. A method for treating one or more	Y	N	N
		PCT/IB2020/05368 4	TREATING NEUROCOGNITIVE	Pathfinder Limited	neurocognitive disorders in a subject in need thereof, the method comprising administering			

Priority documents: CHRONIC PAIN amount of psilocybin or an active metabolite	
U.S. 62/946.159 AND REDUCING thereof.	
(12/10/2019) INFLAMMATION	
U.S. 62/893.611 5. The method of any one of claims 1-4.	
(08/29/2019) wherein the subject has at least one	
US 62/893 110 comorbidity, and wherein administration of	
(08/28/2019) psilocybin ameliorates the comorbidity.	
U.S. 62/835 485	
(04/17/2019) 6 The method of claim 5 wherein the	
US 62/835 484	
(04/17/2019) tissue disease depression, diabetes or chronic	
US 62/835 482	
(04/17/2019)	
U S 62/835 481	
(04/12/019) 7. A method for treating a Parkinsonian	
US 62/835 480 syndrome or symptom thereof in a subject in	
(04/17/2019) need thereof, the method comprising	
US 62/835 479	
(04/17/2019) therapeutically effective amount of	
US 62/835 478 psilocybin or an active metabolite thereof.	
04/17/2019	
U.S. 62/835 477	
(04/17/2019) subject has a neuropsychiatric disturbance,	
US 62/835 476	
(04/17/2019) disturbance is dementia, depression,	
US 62/835 474 psychosis, apathy, anxiety, or hallucinations,	
(04/17/2019) or combinations thereof.	
U.S. 62/835.472	
(04/17/2019) 13. A method for treating attention-deficit	
U.S. 62/835 465 hyperactivity (ADHD) disorder in a subject in	
(04/17/2019) need thereof, the method comprising	
U.S. 62/835,464 administering to the subject a	
(04/17/2019) therapeutically effective amount of	
U.S. 62/835,460 psilocybin or an active metabolite thereof.	
(04/17/2019)	
U.S. 62/835,458	
(04/17/2019)	
U.S. 62/835,450	
(04/17/2019) 16 The method of claim 15 wherein the	
U.S. 62/835,449	
(04/17/2019)	
demand using united by biological dependence of the second s	
uter testini, anter, orpota disting a	
disorders personality disorder observe	
computing disorder, or combinations thereof	
computative disorder, or combinations thereof.	
40 A method of treating chronic pain in a	
subject in need thereof the method	
comprising administering to the subject a	

			1	1	1
		therapeutically effective amount of			
		nsilocybin or an active metabolite thereof			
		42 The method of claim 40 wherein			
		42. The method of Claim 40 , wherein			
		administering the psilocybin also			
		ameliorates one or more conditions			
		comorbid with the chronic pain			
		comorbid with the chronic pain.			
		43. The method of claim 42, wherein the			
		condition comorbid with the chronic pain is			
		condition conforbid with the chronic pain is			
		a mood disorder.			
		44. The method of claim 43 , wherein the			
		44. The method of claim 45 , wherein the			
		mood disorder is depression.			
		47 A method of reducing inflammation in a			
		47. A memou of reducing minamination in a			
		subject in need thereof, the method			
		comprising administering to the subject a			
		therementically effective emount of			
		inerapeutically effective amount of			
		psilocybin or an active metabolite thereof.			
		54. The method of any one of claims 47-52.			
		where is and a size is flower of the in the			
		wherein reducing inflammation in the			
		subject treats or prevents a mood disorder			
		in the subject			
		in the subject.			
		55. The method of claim 54, wherein the			
		mood disorder is depression			
		inood disorater is depressioni			
		66 A mathed for treating a subject in need			
		oo. A method for treating a subject in need			
		thereof, the method comprising			
		administering to the subject a			
		therementically effective emerget of			
		merapeutically effective amount of			
		psilocybin or an active metabolite thereof;			
		wherein the subject is recovering from a stroke			
		69 The method of any one of claims 63, 68			
		ob. The method of any one of claims 05- 00,			
		wherein the subject has depression.			
		70. The method of claim 69 wherein the			
		administration of pails			
		auministration of pshocydin aneviates			
		depression in the subject.			
		- *			
		71. A method for treating amyotrophic lateral			
		sclerosis (AIS) a subject in need thereof the			
		scierosis (ALS) a subject in need meleor, the			
		method comprising administering to the			
		subject a therapeutically effective amount			
		of nailoovhin on an active metabolit- 4f			
		or pshocyphil or an active metabolite thereof.	1	1	1

					74. The method of any one of claims 71_{-} 73			
					wherein the subject has depression			
					wherein the subject has depression.			
					75 The method of claim 74 wherein the			
					administration of psiloayhin alleviates			
					doministration of pshocybin aneviates			
11020220000002		HO D .		<i></i>	depression in the subject.	37	N 7	Ŋ
US20230000883	Pending	U.S. Patents	Methods for treating	Compass	1. A method of treating an anxiety disorder	Ŷ	N	N
		11564935	anxiety disorders,	Pathfinder	in a subject in need thereof, the method			
		11/38035	headache disorders,	Limited	comprising administering to the subject a			
			and eating disorders		therapeutically effective amount of			
		U.S. applications	with psilocybin		crystalline psilocybin, wherein the			
		18/210,526			crystalline psilocybin is characterized by			
					XRPD peaks at 11.5 ± 0.1 , 12.0 ± 0.1 , 14.5 ± 0.1 ,			
		WIPO			17.5 ± 0.1 and $19.7\pm0.1^{\circ}2\theta$, and wherein the			
		applications			crystalline psilocybin has a chemical purity			
		PCT/IB2020/05368			of greater than 97% as determined by HPLC			
		7			analysis.			
					8. The method of alaim 1, wherein the			
		Priority documents			8. The method of claim 1, wherein the			
		U.S. 62/946,159			subject has one of more conditions			
		(12/10/2019)			comorbid with an anxiety disorder.			
		U.S. 62/893,611			0 The wether dief claims 8 web ensity the end of			
		(08/28/2019)			9. The method of claim 8, wherein the one of			
		U.S. 62/893,110			more conditions comorbid with an anxiety			
		(08/28/2019)			disorder is a mood disorder, major			
		U.S. 62/835,485			depressive disorder, bipolar disorder,			
		(04/17/2019)			schizophrenia, an eating disorder, attention			
		U.S. 62/835,482			deficit/nyperactivity disorder, epilepsy,			
		(04/17/2019)			cardiovascular disease, migraine, a neadache			
		U.S. 62/835,481			disorder, irritable bowel syndrome, dementia,			
		(04/17/2019)			Alzheimer's disease, Parkinson's disease, or			
		U.S. 62/835,484			combinations thereof.			
		(04/17/2019)			11 A method of an and an an traction			
		U.S. 62/835,480			11. A method of preventing or treating a			
		(04/17/2019)			cluster neadacne in a subject in need			
		U.S. 62/835,479			inereoi, ine method comprising			
		(04/17/2019)			administering to the subject a			
		U.S. 62/835,478			therapeutically effect amount of crystalline			
		(04/17/2019)			psilocybin, wherein the crystalline psilocybin			
		U.S. 62/835,477			is characterized by AKPD peaks at			
		(04/17/2019)			$11.5 \pm 0.1, 12.0 \pm 0.1, 14.5 \pm 0.1, 17.5 \pm 0.1$ and			
		U.S. 62/835,476			19. $/\pm 0.1^{\circ}20$, and wherein the crystalline			
		(04/16/2019)			psilocybin has a chemical purity of greater			
		U.S. 62/835,474			than 91% as determined by HPLC analysis.			
		(04/17/2019)						
		U.S. 62/835,472			13. The method of claim 11, wherein the			
		(04/17/2019)			subject has one or more diseases, disorders,			
		U.S. 62/835.465			or conditions comorbid with a cluster			
		(04/17/2019)			headache.			

LLC 62/025 161				
0.3. 02/833,404				
(04/17/2019)		14. The method of claim 13, wherein the one		
U.S. 62/835,460		or more diseases, disorders, or conditions		
(04/17/2019)		comorbid with a cluster headache is sleep		
U.S. 62/835 458		annea depression anxiety aggressive		
(04/17/2010)		hehewior suisidal idention or hinglar disorder		
(04/17/2019)		benavior, suicidar ideation, or orporar disorder.		
U.S. 62/835,450				
(04/17/2019)		16. A method of preventing or treating a		
U.S. 62/835,449		migraine in a subject in need thereof, the		
(04/17/2019)		method comprising administering to the		
(*********		subject a therapoutically affect amount of		
		subject a incrapeutically effect amount of		
		crystanine pshocybin, wherein the crystanine		
		psilocybin is characterized by XRPD peaks		
		at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and		
		19.7±0.1°20, and wherein the crystalline		
		nsilocyhin has a chemical purity of greater		
		then 07% as determined by HPLC analysis		
		than 97% as determined by HFLC analysis.		
		19. The method of claim 16 , wherein the		
		subject has one or more diseases, disorders,		
		or conditions comorbid with a migraine.		
		20. The method of claim 10, wherein the one		
		20. The method of claim 19 , wherein the one		
		or more diseases, disorders, or conditions		
		comorbid with a migraine is stroke, vascular		
		brain lesions, coronary heart disease, patent		
		foramen ovale, hypertension, depression,		
		anxiety bipolar disorder panic disorder		
		suicide restless les syndrome enilensy		
		suicide, resuess leg syndronic, epitepsy,		
		inflammatory bowel disease, or asthma.		
		22. A method for treating an eating disorder		
		in a subject in need thereof, the method		
		comprising administering to the subject a		
		theraneutically effective amount of		
		any stalling neilogybin, wherein the		
		ci ystannie psnocybin, wnerein the		
		crystalline psilocybin is characterized by		
		XRPD peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1,		
		17.5±0.1 and 19.7±0.1°20, and wherein the		
		crystalline psilocybin has a chemical purity		
		of greater than 97% as determined by HPLC		
		analysis		
		anarysis.		
		27. The method of claim 22, wherein the		
		subject has one or more conditions		
		comorbid with an eating disorder.		
		28 The method of claim 27 wherein the one		
		26. The method of claim 27, wherein the one		
		or more conditions comorbid with an eating		

					disorder is obesity, one or more conditions related to obesity, or both. 31. The method of claim 27, wherein the one or more conditions comorbid with an eating disorder is a psychiatric disorder selected from the group consisting of schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, autism, alcohol use disorder, drug use disorder, and suicide attempt.			
US20230233584	Pending	WIPO applications PCT/IB2021/00048 8 Priority documents U.S. 63/058,386 (07/29/2020)	EXTENDED RELEASE 5-HT RECEPTOR AGONISTS FOR NEUROLOGICAL CONDITIONS	Diamond Therapeutics Inc.	 40. A method for improving symptoms of a cognitive or neuropsychiatric disorder, in an individual in need thereof, comprising: a. administering to the individual a therapeutically effective amount of psilocybin or psilocin, or a pharmaceutically acceptable salt thereof, and b. maintaining a plasma concentration of an active form of psilocybin or psilocin (i) at or above a minimum therapeutically effective threshold in the individual and (ii) below a hallucinogenic threshold in the individual for more than or equal to two hours. 46. The method of claim 40, wherein the cognitive or neuropsychiatric disorder is an anxiety, attention, or depression disorder. 47. The method of claim 46, wherein the depression disorder is major depressive disorder. 59. The method of claim 40, wherein the therapeutically effective amount of psilocybin or psilocin, or a pharmaceutically acceptable salt thereof is administered orally. 	Y	Y	Ν
US20220273680	Pending	U.S. applications 17/940,950 WIPO applications PCT/US2020/04614 9 Priority documents U.S. 62/886,090 (08/13/2019)	Methods of Treating Psychological and Brain Disorders	University of Maryland, Baltimore	 A method for preventing or treating a psychological disorder, comprising the step of: administering a serotonin agonist in combination with a serotonin receptor 2A antagonist, wherein said agonist is administered separately, sequentially or simultaneously with said antagonist. The method of claim 1, wherein said serotonin agonist is psilocybin, psilocin, 	Y	N	Ν

			baeocystin, norbaeocystin, lisurgide, LSD,		
			dimethyltryptamine. carboxamindotryptamine,		
			ibogaine, 3,4-methylenedioxy-		
			methamphetamine (MDMA) or a compound		
			that promotes a release of serotonin or a		
			combination thereof.		
			11 The method of claim 1 wherein the		
			nswehological disordar is depression		
			psychological disorder ashizonbrania		
			psycholic disorder, schizophreina,		
			schizophreniform disorder (acute		
			schizophrenic episode), schizoaffective		
			disorder; bipolar I disorder (mania, manic		
			disorder, manic-depressive psychosis), bipolar		
			II disorder, major depressive disorder with		
			psychotic feature (psychotic depression),		
			delusional disorders (paranoia), shared		
			Psychotic Disorder (shared paranoia disorder),		
			Brief Psychotic disorder (other and		
			unspecified Reactive Psychosis), psychotic		
			disorder not otherwise specified (unspecified		
			nsychosis) paranoid personality disorder		
			schizoid personality disorder schizotynal		
			personality disorder anyiety disorder panic		
			disorder, panic attacks, agoraphobia, attention		
			deficit sundrome, promonstruel dusphorie		
			disorder promonstrual supdrama ADUD		
			ADD anomalia namena antianaial namenality		
			ADD, anorexia nervosa, antisocial personanty		
			personality disorder, bipolar disorder, bulimia		
			nervosa, borderline personality disorder,		
			catatone schizophrenia, chronic motor or vocal		
			tic disorder, conversion disorder, cyclotnymia,		
			dependent personality disorder, delier,		
			dementia, depersonalization disorder,		
			depression, Dhat syndrome, dissociative		
			amnesia, dissociative fugue, dissociative		
			identity disorder, dissociative disorder,		
			dissociative disorder, not otherwise specified,		
			dysthymic disorder, Da Costa's syndrome,		
			ephobophilia, exhibitionism, generalized		
			anxiety disorder, grandiose delusions,		
			hypochondria, hoarding disorder, intermittent		
			explosive disorder, jealousy, kleptomania,		
			Kluver-Bucy syndrome, maternity psychosis,		
			mental retardation, monomania, Munchhausen		
			syndrome, misophony, narcissistic personality		
			disorder, obsessive-compulsive disorder,		
			oniomania, organic personality disorder,		
			phobia, paranoid personality disorder,		

		1		1	
			paranoid delusions, passive-aggressive		
			personality, pathological gambling.		
			pathological lying personality disorder not		
			the mating defined as marked as a least a market		
			otherwise defined, pervasive developmental		
			disorder, pica, pain disorder, post encephalitic		
			syndrome, postpartum depression,		
			posttraumatic stress disorder, psychosis		
			psychotic disorder due to substance use		
			psycholic disorder due to substance dse,		
			pyromania, querulant delusions, ruminational		
			disorder, schizophrenia, schizoaffective		
			disorder, schizoid personality disorder,		
			schizotypal personality disorder, separation		
			anxiety social phobia somatisation disorder		
			somatic delusion, somatoform disorder		
			syndrome of Capgras, syndrome of Cotard,		
			syndrome of Ganser, syndrome of Gilles de la		
			Tourette, selective mutism, theatrical		
			personality disorder, trichotillomania or		
			undifferentiated somatoform disorder		
			undifferentiated somatororin disorder.		
			12. A method for preventing or treating a		
			psychological disorder, comprising the step		
			of: administering an agonist of serotonin		
			receptors in combination with a serotonin		
			recentor 2A antagonist wherein said agonist		
			is administered separately, sequentially or		
			is administered separately, sequentially of		
			simultaneously with said antagonist.		
			The method of claim 12, wherein said		
			agonist of serotonin receptors is an agonist		
			of serotonin receptor 1B, serotonin receptor		
			4 serotonin recentor 6 or serotonin		
			vecenter 7		
			receptor 7.		
			18. The method of claim 13 , wherein said		
			serotonin agonist is a derivative of		
			psilocybin or psilocin.		
			1		
			24. The method of claim 12, wherein the		
			psychological disorder is depression,		
			psychotic disorder, schizophrenia,		
			schizophreniform disorder (acute		
			schizophrenic episode) schizoaffective		
			diagnal and the stand diagnal of the standard diagnal		
			disorder; bipolar I disorder (mania, manic		
			disorder, manic-depressive psychosis), bipolar		
			II disorder, major depressive disorder with		
			psychotic feature (psychotic depression).		
			delusional disorders (paranoia), shared		
			Psychotic Disorder (shared paranoia disorder)		
			Drief Davahotia disorder (sther and		
			brief Psycholic disorder (other and		

		unspecified Reactive Psychosis), psychotic		
		disorder not otherwise specified (unspecified		
		psychosis), paranoid personality disorder,		
		schizoid personality disorder, schizotypal		
		personality disorder, anxiety disorder, panic		
		disorder, panic attacks, agoraphobia, attention		
		deficit syndrome, premenstrual dysphoric		
		disorder, premenstrual syndrome, ADHD,		
		ADD, anorexia nervosa, antisocial personality		
		disorder, autism, addiction, avoidant		
		personality disorder, bipolar disorder, bulimia		
		nervosa, borderline personality disorder,		
		catatone schizophrenia, chronic motor or vocal		
		tic disorder, conversion disorder, cyclothymia,		
		dependent personality disorder, delier,		
		dementia, depersonalization disorder.		
		depression. Dhat syndrome, dissociative		
		amnesia, dissociative fugue, dissociative		
		identity disorder, dissociative disorder.		
		dissociative disorder, not otherwise specified.		
		dysthymic disorder. Da Costa's syndrome		
		ephobophilia exhibitionism generalized		
		anxiety disorder grandiose delusions		
		hypochondria hoarding disorder intermittent		
		explosive disorder, jealousy, kleptomania		
		Kluver-Bucy syndrome maternity psychosis		
		mental retardation monomania Munchhausen		
		syndrome misonhony parcissistic personality		
		disorder obsessive_compulsive disorder		
		oniomania, organic personality disorder		
		phobia personality disorder		
		prioria, paranoia personanty disorder,		
		paranolity nothological combling		
		personality, pathological gamolity,		
		otherwise defined remains developmental		
		disorder nice, pein disorder next encembelitie		
		usoruer, pica, pair usoruer, post encephantic		
		syndrome, postpartum depression,		
		positiaumatic stress disorder, psychosis,		
		psychotic disorder due to substance use,		
		pyromania, querulant delusions, ruminational		
		disorder, schizophrenia, schizoaffective		
		disorder, schizoid personality disorder,		
		schizotypai personality disorder, separation		
		anxiety, social phobia, somatisation disorder,		
		somatic defusion, somatoform disorder,		
		syndrome of Capgras, syndrome of Cotard,		
		syndrome of Ganser, syndrome of Gilles de la		
		Tourette, selective mutism, theatrical		
		personality disorder, trichotillomania, or		
		undifferentiated somatoform disorder.		

US20220323378	Pending	Priority documents U.S. 63/170,486 (04/03/2021) U.S. 63/173,795 (04/12/2021) U.S. 63/177,601 (04/21/2021) U.S. 63/245,592 (09/17/2021) U.S. 63/247,773 (09/23/2021) U.S. 63/277,998 (11/10/2021)	Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity	Shawn Joseph	 A composition comprising a serotonergic psychedelic compound and a ketamine compound in synergistically effective amounts for treating a patient suffering from a brain condition or disorder and/or promoting neural plasticity in a patient in need thereof. The composition of claim 1, wherein the serotonergic psychedelic compound is selected from the group consisting of psilocybin, psilocin, a psilocybin derivative, tryptamine, phenethylamine, lysergamide, and one or more combinations thereof. The composition of claim 1, wherein the psychedelic compound is selected from the group consisting of psilocybin, psilocin, and a psilocybin derivative. A composition according to claim 1, wherein the brain condition or disorder is depression. A method of treating a patient suffering from a brain condition or disorder and/or promoting neural plasticity in a patient in need thereof comprising administering to the patient a composition according to claim 1. The method of claim 7, wherein the brain condition or disorder comprises a major depressive disorder. 	Ν	Ν	Y

U\$20220016104	Pending	U.S. Patents	COMPOSITIONS	Turtle Bear	1 A method for reducing symptoms of	N	V	V
0.520220010104	Tenung	<u>11590120</u>	AND METHODS	Holdings LLC	depression or anyiety in a subject in need	1	1	1
		11590120	FOR TREATING	Holdings ELC	thereof comprising: administering a			
		U.S. applications	DEPRESSION		therapeutically effective amount of a			
		<u>16/211 281</u>	DEI RESSION		composition comprising psilocybin or			
		15/494 503			psilocin sufficient to reduce the symptoms of			
		15/4/4,505			depression or anxiety in the subject			
		Priority documents			depression of anxiety in the subject.			
		$\frac{11010y}{115} 4000000000000000000000000000000000000$			4 The method of claim 1 whorein the			
		(07/23/2016)			4. The method of claim 1, wherein the			
		(07/23/2010)			ma to 0.6 ma; 0.6 ma to 0.0 ma; 0.0 ma to 10			
					mg to 0.0 mg to 10 mg of psilocybin or			
					ng, of 1 mg to 10 mg of pshocyom of			
					mass			
					mass.			
					7. The method of claim 1 , wherein the			
					composition is administered in a capsule.			
					11. A method for reducing symptoms of			
					depression or anxiety in a subject in need			
					thereof comprising: administering a			
					composition comprising 0.1 mg to 10 mg of			
					psilocybin or psilocin per 70 kg of the			
					subject's body mass sufficient to reduce the			
					symptoms of depression or anxiety in the			
					subject.			
					14. The method of claim 11, wherein the			
					composition comprises 0.1 mg to 10 mg; 0.1			
					mg to 0.6 mg; 0.6 mg to 0.9 mg; 0.9 mg to 10			
					mg; or 1 mg to 10 mg of psilocybin or			
					psilocin per 70 kg of the subject's body mass.			
					17. The method of claim 11. wherein the			
					composition is administered in a capsule.			
					The second se			
US20230218603	Pending	U.S. Patents	PSILOCYBIN	Turtle Bear	1. A method for reducing symptoms of	Ν	Ν	Ν
	-	11590120	COMPOSITIONS	Holdings LLC	depression in a subject in need thereof, the			
				-	method comprising:			
		U.S. applications			administering a dosage form comprising:			
		16/211,281			0.1 to 10 mg of baeocystin, norbaeocystin,			
		15/494,503			salts thereof, or combinations thereof; and			
					1 to 50 mg of niacin;			
		Priority documents			sufficient to reduce the symptoms of			
		U.S. 62/365,982			depression in the subject.			
		(07/23/2016)						
					2. The method of claim 1 , wherein the dosage			
					form further comprises 0.1 to 10 mg of			
					psilocybin, psilocin, salts thereof, or			
					combinations thereof.			

LIS20230059204	Pending	Priority documents	TRANSDERMAL	Pike	1 A transdermal and/or tonical	N	N	Y
0020230037201	renang	U.S. 63/229.015	MICRO-DOSING	Therapeutics	nharmaceutical composition comprising	11	11	1
		(08/03/2021)	DELIVERY OF	Inc.	at least one active agent selected from the			
		US 63/324 288	PHARMACEUTICAL	inc.	group consisting of			
		(03/28/2022)	AGENTS		about 0.1% to about 50% of an active agent			
		(03/20/2022)	NGENIB		selected from the group consisting of			
					tetrahydrocannahinol (THC) cannahidiol			
					(CBD) psilocybin psilocin lysergic acid			
					diathylamina (LSD), and/or ibogaina the free			
					has thereof salts thereof isomers thereof			
					amorphous forms thereof, amorphous forms			
					thereof as arestalling forms thereof prodrugs			
					thereof, co-crystamme forms thereof, produces			
					surthering forms thereof, neturally derived			
					for the set of the set			
					forms thereof, active metabolites thereof,			
					polymorph thereof, solid solution thereof,			
					coated form thereof, and combinations thereof,			
					further wherein the pharmaceutical			
					composition comprises:			
					about 10% to about 99.9% of an addesive			
					and/or polymer;			
					optionally, about 0.1% to about 99% of a			
					permeation ennancer;			
					optionally, about 0.1% to about 99% of a			
					solvent,			
					wherein said pharmaceutical composition will			
					nave no or minimal nallucinogenic or			
					psychoactive effect in a patient to whom the			
					pharmaceutical composition is applied.			
					2 The abarrantical compatition of alatin			
					5. The pharmaceutical composition of claim			
					1, wherein the pharmaceutical formulation			
					provides a dose of active agent to a patient			
					equal to or greater than, for example, about			
					0.001 ng/day, 0.01 ng/day, 0.025 ng/day, 0.05			
					ng/day, 0.1 ng/day, 0.25 ng/day, 0.5 ng/day, 1			
					ng/day, 10 ng/day, 25 ng/day, 50 ng/day, 100			
					ng/day, 250 ng/day, 500 ng/day, 1000 ng/da			
					0.001 microgram/day, 0.01 microgram/day,			
					0.025 microgram/day, 0.050 microgram/day,			
					0.1 microgram/day, 0.25 microgram/day, 0.5			
					microgram/day, 1 microgram/day, 2.5			
					microgram/day, 5 microgram/day, 10			
					microgram/day, 25 microgram/day, 50			
					microgram/day, 100 microgram/day, 250			
					microgram/day, 500 microgram/day, about			
					0.001 mg/day, 0.01 mg/day, 0.025 mg/day.			
					0.05 mg/day, 0.1 mg/day, 0.25 mg/day, 0.5			
					mg/day, 1 mg/day, 10 mg/day, or 25 mg/day.			

					33. The pharmaceutical composition of claim 1 indicated for the treatment and/or prevention and/or control of chronic pain, multiple sclerosis, severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, post- traumatic stress disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adjustment disorder, prolonged grief disorder (PGD), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress in a patient.			
WO2022261263	Publish ed	Patent family members: No relevant national stage applications have been published for this family at the date of generation of this document <u>Priority documents</u> U.S. 63/208,339 (06/08/2021) U.S. 63/298,493 (01/11/2022)	Methods of treating neuropsychiatric disorders	Gilgamesh Pharmaceutica ls, Inc.	 A method of treating a neuropsychiatric disorder in a patient in need thereof, comprising administering to the patient an effective amount of an orexin receptor antagonist and further comprising administering to the patient an effective amount of a serotonin receptor agonist or an NMD A receptor antagonist. The method of any of claims 1-49, wherein the serotonin receptor agonist is psilocybin. The method of any of claims 1-49, wherein the serotonin receptor agonist is psilocybin. The method of any of claims 1-49, wherein the psilocybin is administered orally at a dose of 1-40 mg. The method of claim 67, wherein the psilocybin is administered as an oral dosage form, wherein, the oral dosage form comprises: crystalline psilocybin in the form Polymorph A characterized by peaks in an XRPD diffractogram at 11.5, 12.0, 14.5, 17.5, and 19.7°2Q±0.1°2Q, wherein the crystalline psilocybin has a chemical purity of greater than 97% by HPLC, and silicified microcrystalline cellulose. The method of any of claims 1-86, wherein the neuropsychiatric disorder is a mood disorder. The method of claim 87, wherein the mood disorder is depression. 	N	N/A	N

					89. The method of claim 88 , wherein the depression is selected from the group consisting of major depressive disorder , persistent depressive disorder, postpartum depression, premenstrual dysphoric disorder, seasonal affective disorder, psychotic depression, disruptive mood dysregulation disorder, substance/medication-induced depressive disorder, prolonged or pathological grief, and depressive disorder due to another medical condition.			
WO2022195489	Publish ed	Patent family members: No relevant national stage applications have been published for this family at the date of generation of this document <u>Priority documents</u> U.S. 63/161,070 (3/15/2021)	IMPROVED METHODS FOR THE USE OF PSYCHEDELICS	Tryp Therapeutics, Inc.	 A method of treating a psychological disorder in a subject, the method comprising: administering to a subject having a psychological disorder an amount of the psychelic sufficient to induce a dissociative state in the subject less than 30 minutes after administration; and thereafter maintaining the mean plasma concentration of the psychedelic at a predetermined value to maintain the dissociative state during a therapeutic window; wherein the psychedelic is psilocybin, psilocin, a co-crystal, a co- former, or a salt thereof, or a combination thereof. The method of any one of claims 1-8, wherein the administration of the psychedelic is by intravenous administration. The method of any one of claims 1, 6, 7, and 9-43, wherein the mean plasma concentration of the psychedelic is maintained at the predetermined value during the therapeutic window by administration of a maintenance dose of the psychedelic. The method of claim 44, wherein the maintenance dose of the psychedelic. The method of claim 45, wherein the maintenance dose of the psychedelic is administration of the psychedelic. 	Ν	N/A	Y

					transdermal, intramuscular, intranasal, intranasal/pharanygeal, or buccal route.			
					63. The method of any one of claims 1-62,			
					wherein the total amount of psychedelic that is administered to the subject is up to at or			
					about 1.0 mg, 1.5 mg, 2.5 mg, 5 mg, 7.5 mg,			
					10 mg, 15 mg or 20 mg per subject, or a			
					range defined by any of the foregoing.			
					78. The method of any one of claims 1-7 and			
					9-77, wherein the psychological disorder is selected from the group consisting of PTSD			
					alcohol addition, drug addiction, treatment			
					resistant depression, anxiety, end of life			
					neuropathic pain, phantom limb pain,			
					hypothalamic induced obesity, Prader-Willi			
					syndrome, and binge-eating disorder.			
WO2022212854	Publish	Patent family	Methods and	Terran	44. A method of treating a disease or	N	N/A	N
	ed	<u>members</u> : No relevant national	compositions relating	Biosciences	disorder in a subject in need thereof, the method comprising administering to the			
		stage applications	serotonin receptor	University of	subject a composition comprising: a) a			
		have been published	modulators	Maryland, Baltimore	psychedelic; b) a serotonin receptor			
		date of generation		Battinole	serotonin receptor modulator is released at			
		of this document			most about 3 hours prior to the release of the			
					psychedenc.			
		Priority documents			45. The method of claim 44 , wherein the			
		(04/01/2021)			disease or disorder is depression or a disease			
		U.S. 63/274,308			or disorder related to depression.			
		U.S. 63/294,801			46. The method of claim 44 , wherein the			
		(12/29/2021)			depression is major depressive disorder,			
		(02/09/2022)			disorder, treatment resistant depression			
					(TRD), postpartum depression, premenstrual			
					dysphoric disorder, or seasonal affective disorder.			
					57 The method of any one of claims 44 47			
					wherein the psychedelic is psilocybin or a			
					pharmaceutically acceptable salt, solvate,			
					prodrug thereof.			

					90 The method of any one of cloims 44.74			
					80. The method of any one of claims 44-74,			
					dage of a bart 10 ma to short 100 ma			
1100000001114500	D 11'1	D		D I	dose of about 10 mg to about 100 mg.	NT.	NT / A	Ŋ
WO2023114529	Publish	Patent family	PHARMACOACTIVE	Bennes, Inc.	1. A lozenge for rapid delivery of a	N	N/A	N
	ed	members:	FORMULATIONS		psychedelic compound through the oral			
		No relevant national	FOR DELIVERY OF		mucosa, the lozenge comprising: a water-			
		stage applications	PSYCHEDELIC		insoluble polymer; and one or more			
		have been published	COMPOUNDS		psychedelic compounds.			
		for this family at the						
		date of generation			4. The lozenge of claim 1, wherein the			
		of this document			psychedelic compound is selected from a 5-			
					HT2A agonist selected from LSD,			
					psilocybin , DOI (±)-1-(2,5-dimethoxyphenyl)-			
		Priority documents			2-aminopropane hydrochloride; (R)-DOI ((R)-			
		U.S. 63/291,333			l-(2,5-dimethoxy-4-iodophenyI)-2-			
		(12/17/2021)			aminopropane); LA-SS-Az (2'S,4'S)-(+)-9,10-			
					Didehydro-6-methylergoline-8B-(trans-2,4-			
					dimethyl-azetidide); 2C-BCB (4-Bromo-3,6-			
					dimethoxybenzocyclobuten-l-yl)			
					methylamine); ayahuasca; 3,4,5-			
					trimethoxyphenethylamine (mescaline); 5-			
					methoxy-N,N-dimethyltryptamine (5-meo-			
					DMT) and ibogaine, and combinations thereof.			
					8. The lozenge of claim 1, wherein the			
					psychedelic agent is used to treat at least			
					one symptom selected from of obsessive			
					compulsive disorder (OCD), pain, chronic			
					pain, anxiety disproportionate to severity of			
					physical complaints, psychological disorder,			
					major depression, melancholic depression,			
					atypical depression, dysthymia, pain disorder,			
					body dysmorphia, conversion, hysteria,			
					neurological conditions without identifiable			
					cause, psychosomatic illness, pain			
					management in relation to existing physical			
					condition, irritability, fibromyalgia, post-			
					traumatic stress disorder (PTSD), cluster			
					headaches, paranoia, psychosis, anxiety, panic			
					attacks, flashbacks, smoking addiction, alcohol			
					addiction, cocaine addiction, improving			
					creativity, boosting physical energy level,			
					attaining emotional balance, increasing			
					performance on problems-solving tasks,			
					treating anxiety, treating depression, treating			
					addiction, or any combination thereof.			
					20. A method for making a lozenge			
					according to claim 1, the method			
					comprising: (i) preparing an admixture of			

w02022061190 Pablish Patent family. NOVEL Pydecine numbers in a sevential oil and a sweetening agent; and in a sevential oil and a sweetening agent; and in a sweetening agent; and in a sweetening agent; and is off, pliable, and tacky locange metrial is formed. N N w02022061190 Pablish Patent family. NOVEL Pydecine Introduction on temperature and introduction of the step of administering to a sevential oil and a sweetening a servicinin. N N w120222061190 Pablish Patent family. Podecine Innovations receptor related disease or compound, where in said a state or generation of this family at the dise of generation of this family at the disease or compound, where in said entactogen compound, where in said entactogen compound and an entactogen compound without side entactogen compound. N N VUS. 63080.679 WOTH 3.4 A METHANPHETAMI NE (MDMA) NE (MDMA) Intervention by said entactogen compound without side entactogen compound and entactogen compound and entactogen compound without side entactogen compound entactogen compound entactogen compound entactogen compound entactogen						0.10-200 mg of a desired psychedelic			
W02022061196 Publish ed Patent family members: No national stage opplications have been published for date of generation of this family at the same been published for this family at the same been published for this family at the date of generation of this document been published for this document of this document of this document of this document been published for this document of this document of this document of this document of this document been published for this document of this document of this document of this document been published for this document of this document of this document of this document of this document been published for this document been published for this document of this document of this document been published for this document been published for this document of this document been published for this document been publ						compound, ethyl cellulose, and optionally, an			
woddling Patient family members: op national stage NOVEL PORMULATIONS OF SELOCYBIN AGONSTS IN COMPOUNDS AS SEROTONIN of this document of this document US, 63080,679 (09/18/2020) NOVEL PORMULATIONS FOR SELOCYBIN AGONSTS IN COMPOUNDS AS SEROTONIN AGONSTS IN COMPOUNDS AS SEROTONIN MCTHYLENEDIDOXY WITH 3.4 WETHYLENEDIDOXY MCTHAMPHIETAMI NE (MDMA) Mydecine Innovations from price organization of this document O(MPROUNDS AS SEROTONIN AGONSTS IN COMPOUNDS AS SEROTONIN MCTHYLENEDIDOXY MCTHAMPHIETAMI NE (MDMA) NMA NMA VIETA INFORMULATIONS AGONSTS IN COMPOUNDS AS SEROTONIN AGONSTS IN COMPOUNDS AS SEROTONIN MCTHYLENEDIDOXY MCTHAMPHIETAMI NE (MDMA) NMA N N VIETA INFORMULATION WITHY 3.4 WETHYLENEDIDOXY (09/18/2020) Priority documents US, 63080,679 (09/18/2020) N N N VIETA INFORMULATION WITHYLENEDIDOXY (09/18/2020) N N N N N VIETA INFORMULATION WITHYLENEDIDOXY (09/18/2020) N N N N N VIETA INFORMULATION WITH 3.4 WETHYLENEDIDOXY (09/18/2020) N N N N VIETA INFORMULATION (09/18/2020) N N N N VIETA INFORMULATION (09/18/2020) </td <td></td> <td></td> <td></td> <td></td> <td></td> <td>essential oil and a sweetening agent; and (ii)</td> <td></td> <td></td> <td></td>						essential oil and a sweetening agent; and (ii)			
WO2022061196 Publish ed Patent family: members: No national stage opplications have been published for this family at members: No national stage opplications have been published for date of generation of this documents U.S. 63 080,679 NOVEL FORMULATIONS ADD PESILOCIN COMPOUNDS AS SERCITONIN AGONISTS IN COMPOUNDS AS SERCITONIN AGONISTS IN SERCITONIN AGONISTS IN COMPOUNDS AS SERCITONIN AGONISTS IN COMPOUNDS AS SERCITONIN AGONISTS IN SERCITONIN AGONISTS IN SERCITONIN AGONISTIN SERCITONIN AGONISTIN SERCITONIN AGONISTIN SERCITONIN AGONISTIN S						setting the admixture at room temperature and			
WO2022061196 Publish Patent family members: AND PSILOCYBIN on ational stage applications have been published been date of generation of this document of this document (09/18/2020) NV/A N VI A NOVEL Fronty documents (09/18/2020) NV/A N N N/A N VI A NOVEL Fronty documents (09/18/2020) NV/A N N N/A N VI A N N N/A N N N VI A N N N N N						ambient humidity until a soft, pliable, and			
WO2022061196 Pelabish Patent iamity NOVEL Mydcene 124. Anethod of treating a serotomin N N N N ed det members: FORMULATIONS Mydcene 124. Anethod of treating a serotomin N N N N N of Bialcoursh OF PSILOCYBIN Group Inc Singer administering to a subject in need disease or condition, comprising the step of administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in need mende togen Singer administering to a subject in subject in need to a subject administering to administering to administering to adminit administering to administering to administe						tacky lozenge material is formed.			
ed members: applications have op FBSLICCYBIN been published for ODE PSLICCYBIN been published date of generations date of generations of this document of this document AND PSLICCYBIN CONDINTS SEROTONIN date of generation (COMBINATION WITH 3.4 METHYLENEDIDXY METHAMPHETAMI NE (MDMA) receptor related disease or condition, stopported, wherein said typamine compound, wherein said typation subject, and wherein said typation subject, and wherein said typation subject, and wherein said typation compound, wherein said typation subject, and wherein said typation without said entactogen. 126. The method of any of claims 124-125, wherein said typation comprises a human subject. 143. The method of claim 143, wherein said buman subject comprises a human subject. 144. The method of any of claims 144-145 wherein said sectorin receptor related disease or condition, depression, obsessive computive disorder (OCD), cluster treated from the group consisting of schizophorin, addiction, depression, obsessive computive disorder (OCD), cluster the adaches, dementia,	WO2022061196	Publish	Patent family	NOVEL	Mydecine	124. A method of treating a serotonin	Ν	N/A	N
No hatchail sidge OF PSLOC PSIN Group inc Comprising the side of administering to a subject in meet thereof, with a the split administering to a subject in meet thereof, with a therapeutically effective amount of a tryptamine compound and an entactogen compound, wherein said cryptamine compound and said entactogen compound and said entactogen. Priority documents U.S. 63/080,679 NETHYLENEDIOXY Subject in method of a subject in eactivated to approximately the same level as the activated to approximately the same level as the activated to approximately the same level as the activation by said tryptamine compound without said entactogen. 126. The method of administration of claims 124-125, wherein said subject comprises a human subject. 143. The method of claims 124, wherein said subject comprises a human subject. 144. The method of claims 144, 145 Werein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 Wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 Wherein said serotonin receptor related disease or condition.		ed	<u>members</u> :	FORMULATIONS	Innovations	receptor related disease or condition,			
approximations have been publications have the approximation of this decument of this documents U.S. 63/080.679 (09/18/2020) AND FURCHARS SEROTONIN COMBUNDS AS SEROTONIN COMBUNATION WITH 3.4 METHYLENEDIOXY METHYLENEDIOXY NE (MDMA) Therapeutically effective anount of a therapeutically effective anount of a therapeutically effective anount of a compound and an entactogen compound and said entactogen activated to approximately the same level as the activation by said tryptamine compound without said entactogen. 126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claims 144-145 wherein said serotomin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotomin receptor related disease or condition is selected from the group consisting of: scitophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster haadachee, dementia,			applications have	AND BSILOC I DIN	Group me	subject in need thereof, with a			
Dots and used CORROTION NO AGONISTS IN AGONISTS IN AGONISTS IN AGONISTS IN AGONISTS IN Compound, wherein said tryptamine Compound, with a service in said tryptamine compound and an entactogen Priority documents WETHAMPHETAMI U.S. 63/080.679 METHAMPHETAMI NE (MDMA) NE (MDMA) 126. The method of any of claims 124-125, wherein said tryptamine compound without said entactogen. 126. The method of claim 124, wherein said subject, and wherein said tryptamine compound comprises psllocybin, or psilocin. 143. The method of claims 124, wherein said subject annuan subject. 144. The method of claims 144, wherein said subject annuan subject. 146. The method of any of claims 144-145 wherein said stropprenia, addiction, depression, obessive compulsite disease or condition.			been published for	COMPOUNDS AS		therapeutically effective amount of a			
AGONISTS IN Compound, wherein said tryptamine coges of this document COMBINATION Distribution COMBINATION WITH 3.4 METHYLENEDIOXY METHYLENEDIOXY subject, and wherein said serotonin receptor a sitivity in sid subject, and wherein said tryptamine compound without said entactogen. U.S. 63/080,679 (09/18/2020) (09/18/2020) NE (MDMA) 126. The method of any of claims 124-125, wherein said wherein said tryptamine compound comprises psllocybin, or psilocia. 143. The method of claim 124, wherein said subject comprises a human subject subject comprises a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of serotonin receptor related disease or condition.			this family at the	SEROTONIN		tryptamine compound and an entactogen			
of this document COMBINATION WITH 3.4 compound and said entactogen compound modulate serotonin receptor activity in said subject, and wherein said serotonin receptor is activated to approximately the same level as the activation by said tryptamine compound without said entactogen. 126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 126. The method of alam 124, wherein said subject comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject. 144. The method of any of claims 141-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 141-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 141-145 wherein said serotonin seecetor related disease or condition. 146. The method of any of claims 141-145 wherein said serotonin seecetor related disease or condition.			date of generation	AGONISTS IN		compound, wherein said tryptamine			
Priority documents U.S. 63/080,679 (09/18/2020) WITH 3,4 METHAMPHETAMI NE (MDMA) modulate serotonin receptor a subject, and wherein said serotonin receptor is subject, and wherein said serotonin receptor is subject. and wherein said serotonin receptor is subject. and wherein said serotonin receptor is the activated to approximately the same level as the activated to approximately the same level suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or complisite disorder (OCD), cluster the methadaches, dementia, addiction, depression, obsessive compulsive disorder			of this document	COMBINATION		compound and said entactogen compound			
Priority documents METHYLENEDIOXY subject, and wherein said serotonin receptor is activated to approximately the same level as the activation by said tryptamine compound without said entactogen. 126. The method of any of claims 124-125, wherein said subject comprises psilocybin, or psilocin. 126. The method of claims 124, hyperein said subject. 143. The method of claim subject. 143. The method of claim subject. 144. The method of claims subject. 144. The method of claim subject comprises a human subject. 144. The method of any of claims subject. 146. The method of any of claims subject. 146. The method of any of claims subject comprises a human subject. 146. The method of any of claims subject. 146. The method of any of claims subject. 146. The method of any of claims subject comprises a human subject comprises a human subject. 146. The method of any of claims subject suffering from serveron related disease or condition. 146. The method of any of claims subject and because or condition. 146. The method of any of claims subject and prove suffering from serveron related disease or condition. 146. The method of any of claims subject and because or condition. 146. The method of any of claims subject and because and prove suffering from serveron related disease or condition. 146. The method of any of claims subject and because and becaus				WITH 3,4		modulate serotonin receptor activity in said			
Priority documents U.S. 63/080.679 (09/18/2020) METHAMPHETAMI NE (MDMA) activated to approximately the same level as the activation by said tryptamine compound without said entactogen. 126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said suffering from, or at risk from suffering from serotonin receptor related disease or condition. 144. The method of any of claims 144-145 wherein said sectorin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said sectorin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said sectorin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder				METHYLENEDIOXY		subject, and wherein said serotonin receptor is			
U.S. 63/080,679 (09/18/2020) NE (MDMA) the activation by said tryptamine compound without said entactogen. 126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 126. The method of claim 124, wherein said subject comprises a human subject. 143. The method of claim 144, wherein said human subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject. 144. The method of any of claims 144-145 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145			Priority documents	METHAMPHETAMI		activated to approximately the same level as			
(09/18/2020) without said entactogen. 126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,			U.S. 63/080,679	NE (MDMA)		the activation by said tryptamine compound			
126. The method of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject comprises a human subject. 144. The method of claim 143, wherein said human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said subject related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,			(09/18/2020)			without said entactogen.			
120. The include of any of claims 124-125, wherein said tryptamine compound comprises psilocybin, or psilocin. 143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 040. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 040. CDD, cluster headaches, dementia,						126. The method of any of claims 124, 125			
143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprises a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition, is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						wherein said tryptamine compound			
143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprise a human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144, 145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144, 145 wherein said serotonin receptor related disease or condition.						comprises psilocybin, or psilocin			
143. The method of claim 124, wherein said subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,									
subject comprises a human subject. 144. The method of claim 143, wherein said human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						143. The method of claim 124, wherein said			
144. The method of claim 143, wherein said human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						subject comprises a human subject			
144. The method of claim 143, wherein said human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,									
human subject comprise a human subject suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						144. The method of claim 143, wherein said			
suffering from, or at risk from suffering from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						human subject comprise a human subject			
from serotonin receptor related disease or condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						suffering from, or at risk from suffering			
condition. 146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						from serotonin receptor related disease or			
146. The method of any of claims 144-145 wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						condition.			
wherein said serotonin receptor related disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						146. The method of any of claims 144-145			
disease or condition is selected from the group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						wherein said serotonin receptor related			
group consisting of: schizophrenia, addiction, depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						disease or condition is selected from the			
depression, obsessive compulsive disorder (OCD), cluster headaches, dementia,						group consisting of: schizophrenia, addiction,			
(OCD), cluster headacnes, dementia,						depression, obsessive compulsive disorder			
Altheimer's disease paralysis attention						(UCD), cluster headacnes, dementia,			
Alzieliner Suiscase, paralysis, auchuon deficit-hyneraetivity disorder (ADHD), eating						deficit-hyperactivity disorder (ADHD) esting			
disorders nost-traumatic stress disorder						disorders post-traumatic stress disorder			
(PTSD), anxiety, and autism.						(PTSD), anxiety, and autism.			
154. The method of any of claims 124-150,						154. The method of any of claims 124-150,			
wherein the dose of psilocybin or psilocin						wherein the dose of psilocybin or psilocin			
compound is in a dosage range of lopg to 1						compound is in a dosage range of 10pg to 1 g/kg or 10pg to 200 mg/kg body weight of			
g/kg or lOpg to 200 mg/kg body weight of the subject being treated, per day						the subject being treated per day			

WO2022115796	Dublish	Priority Documents:	COMPOSITIONS	Wasana	1 A method for reducing a symptom of	v	N/A	v
W02022113790	ad	$\frac{110110y}{110} 1000000000000000000000000000000000000$	AND METHODS	Wesalia Usalth Inc	1. A method for reducing a symptom of	1	11/74	1
	cu	(11/30/2020)	FOR TREATING	meanin me.	syndrome in a subject, the method			
		(11/30/2020)	NEUROLOGICAL		comprising			
			CONDITIONS		(i) administering to the subject at least one			
			conditions		loading dose comprising between about 5			
					mg and 30 mg psilocybin inclusive: and			
					(ii) subsequently administering to the			
					subject at least one maintenance dose			
					comprising between about 0.25 mg to about			
					0.3 mg nsilocybin, inclusive, wherein the			
					subject has been suspected or diagnosed as			
					having traumatic brain injury or post-			
					concussion syndrome.			
					· ·			
					4. The method of any of claims 1 -3, wherein			
					the symptom of traumatic brain injury or			
					post-concussion syndrome comprises			
					anxiety and/or depression.			
					5. The method of any of claims 1 -4 wherein			
					the loading dose comprises about 10 mg			
					psilocybin.			
					6. The method of any of claims 1 -5, wherein			
					the loading dose comprises about 25 mg			
					psilocybin.			
					7. The method of any of claims 1 -6, wherein			
					the loading dose comprises about 30 mg			
					psilocybin.			
					9. The method of any of claims 1 -8, wherein			
					the psilocybin of the loading dose comprises			
					syntnetic psilocybin.			
					10. The method of any of claims 1 -9, wherein			
					the psilocybin of the maintenance dose			
					comprises synthetic psilocybin.			
					79 A method for reducting a method f			
					78. A method for reducing a symptom of			
					syndrome in a subject the method			
					comprising.			
					(i) administering to the subject at least one			
					maintenance dose comprising hetween			
					about 0.25 mg and about 0.3 mg psilocybin			
					inclusive: and			
	1			1				

					(II) auministering to the subject at least one			
					maintenance dose comprising between			
					about 1 mg to about 600 mg of CBD,			
					inclusive, wherein the subject has been			
					suspected or diagnosed as having traumatic			
					brain injury or post-concussion syndrome.			
					79 The method of claim 78 wherein the			
					symptom of traumatic brain injury or			
					nostconcussion syndrome comprises anxiety			
					depression suicide ideation stress post-			
					traumatic stress disorder nost-traumatic			
					hadacha prograssiva hadacha faalings of			
					digginges, pouges, nomiting, poige consistivity			
					being agaily upget by loud poing clean			
					disturbance fatiance antimine many application			
					disturbance, langue or tiring more easily,			
					irritability, insomnia, nervousness, frustration			
					or impatience, forgetfulness or poor memory,			
					poor concentration, taking longer to think,			
					blurred vision, light sensitivity, double vision,			
					restlessness, insomnia, ringing in the ears,			
					blurry vision, decrease in taste and/or smell,			
					and various combinations thereof.			
					80. The method of any of claims 78-79.			
					wherein the symptom of traumatic brain			
					injury or post-concussion syndrome			
					comprises anxiety or depression			
					comprises anxiety of depression.			
					82. The method of any of claims 78-81			
					wherein the symptom of traumatic brain			
					injury or post concussion syndrome			
					apprises depression			
WO2010072270	D1-111-	U.C. Detente	Duran anti- a of	Comment	1 Crustelling a sile authin in the form	V	NT/A	N
w02019075579	Publish	<u>U.S. Patents</u>	Preparation of	Dethermore	Delements A on Delements A!	1	IN/A	IN
	ea	10519175,	psilocybin, different	Patnways	Polymorph A or Polymorph A ,			
		10947257,	polymorphic forms,	Limited	characterised by one or more of:			
		10954259,	intermediates,		a. peaks in an AKPD diffractogram at 11.5,			
		11149044,	formulations and their		12.0 and 14.5 "20±0.1"20;			
		11180517,	use		D. peaks in an AKPD diffractogram at 11.5, $12.0 \text{ m} + 14.5 \text{ (20)} + 0.1020 \text{ f} = 41$			
		1144/510,			12.0 and 14.5 ~2@±0.1~2@, further			
		11505564,			characterised by at least one further peak at			
		11629159			19.7, 20.4, 22.2, 24.3 or 25.7 °2@±0.1°2@;			
					c. an XRPD diffractogram as substantially			
		U.S. Applications			illustrated in Figure 7a or 7b; or d. an			
		17/990,979,			endothermic event in a DSC thermogram			
		18/135,265			having an onset temperature of between 205			
					and 220°C substantially as illustrated in			
		Priority Documents:			Figure 8a or 8b.			

		G B 1716505 1			13 A pharmaceutical formulation			
		(10/09/2017)			comprising crystalling psilogybin in the			
		G B 1810588 2			form			
		(06/29/2019)			Bolymorph A or Bolymorph A' as alaimed in			
		(00/20/2016)			rolymorph A or rolymorph A as claimed in			
		U.D. 1010430.4			any preceding claim.			
		(10/09/2018)						
					14. A pharmaceutical formulation as claimed			
					in claim 13 which is an oral dosage form.			
					15. A pharmaceutical formulation as claimed			
					in claim 13 or 14 wherein the crystalline			
					psilocybin in the form Polymorph A or			
					Polymorph A' is present in an amount			
					providing a dose of from 0.01mg/kg to			
					1mg/kg.			
					21. Crystalline psilocybin in the form			
					Polymorph A or Polymorph A' as claimed			
					in claims 1 to 11 for use in treating drug			
					resistant depression.			
					24. Crystalline psilocybin in the form			
					Polymorph A (12A) for use in in treating			
					drug resistant depression.			
					25. A method of treating drug resistant			
					depression comprising administering to a			
					subject in need thereof an effective dose of			
					crystalline psilocybin in the form			
					Polymorph A (12A).			
WO2023114097	Publish	Patent family	PSILOCYBIN AND	Compass	1. A method of treating treatment-resistant	N	N/A	N
	ed	members:	AN ADJUNCTIVE	Pathfinder	depression in a subject in need thereof, the			
		No national stage	SEROTONIN	Limited	method comprising administering an			
		applications have	REUPTAKE		effective amount of psilocybin or an active			
		been published for	INHIBITOR FOR		metabolite thereof to the subject as an			
		this family at the	USE IN THE		adjunctive to Selective Serotonin Reuptake			
		date of generation	TREATMENT OF		Inhibitor (SSRI) therapy.			
		of this document	TREATMENT-					
			RESISTANT		6. The method of any one of claims 1-5 ,			
			DEPRESSION		wherein about 25 mg of psilocybin or an			
		Priority Documents:			active metabolite thereof is administered to			
		U.S. 63/288,938			the subject.			
		(12/13/2021)						
					35. The method of any one of claims $1-34$			
					wherein the neiloevhin is administered by			
					one of the following routes: oral			
					intravenous intramuscular parenteral topical			
					inhibition rectal transmucosal intranasal			
					huccal vaginal intrathecal intraocular			
					oucear, vaginar, mu'amecar, mu'aocurar,		1	

					 transdermal, in utero, intralymphatic, or by direct tissue or organ injection. 36. The method of claim 35, wherein the psilocybin is administered orally. 45. The method of any one of claims 1-44, wherein the psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis 			
WO2023086252	Publish ed	Patent family members: No national stage applications have been published for this family at the date of generation of this document Priority documents: U.S. 63/284,973 (12/01/2021) U.S. 63/277,407 (11/09/2021)	TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN	Compass Pathfinder Limited	 A method of treating treatment-resistant depression with psilocybin in a subject that did not respond to a first dose of psilocybin, comprising administering a second dose of psilocybin about 3 weeks after administering the first dose of psilocybin. A method of treating treatment-resistant depression in a subject in need thereof, comprising administering a first dose of psilocybin to the subject; measuring the subject's depressive symptoms using a clinical depression evaluation after administering the first dose of psilocybin; identifying the subject as a non-responder to the first dose of psilocybin to the subject 3 weeks after administering the first dose. A method of treating treatment-resistant depression in a subject that responded to a first dose of psilocybin, comprising administering a second dose at least about 26 weeks after administering the first dose. The method of any one of claims 26-28, wherein the subject experiences a reduction in symptoms of depression after administering the first dose of psilocybin. 	Ν	N/A	Ν
WO2023114097	Publish ed	Patent family members: No national stage applications have been published for this family at the date of generation of this document	PSILOCYBIN AND AN ADJUNCTIVE SEROTONIN REUPTAKE INHIBITOR FOR USE IN THE TREATMENT OF TREATMENT- RESISTANT DEPRESSION	Compass Pathfinder Limited	 A method of treating treatment-resistant depression in a subject in need thereof, the method comprising administering an effective amount of psilocybin or an active metabolite thereof to the subject as an adjunctive to Selective Serotonin Reuptake Inhibitor (SSRI) therapy. The method of any one of claims 1-5, wherein about 25 mg of psilocybin or an 	N	N/A	Ν

Priority documents: U.S. 63/288,938 (12/13/2021)	active metabolite thereof is administered to the subject.	
	7. The method of any one of claim 1-6, wherein at least one sign or symptom of depression is reduced by the administration of psilocybin.	
	35. The method of any one of claims 1 -34, wherein the psilocybin is administered by one of the following routes: oral , intravenous, intramuscular, parenteral, topical, inhalation, rectal, transmucosal, intranasal, buccal, vaginal, intrathecal, intraocular, transdermal, in utero, intralymphatic, or by direct tissue or organ injection.	
	45. The method of any one of claims 1-44 , wherein the psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis.	

3. Prior Art References

Scientific publications

Leor Roseman, Lysia Demetriou, Matthew B. Wall, David J. Nutt, Robin L. Carhart-Harris, Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, Neuropharmacology, Volume 142, 2018, Pages 263-269, ISSN 0028-3908, https://doi.org/10.1016/j.neuropharm.2017.12.041

Kuypers KPC. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020 Aug 27;10:2045125320950567. doi: 10.1177/2045125320950567.

Lenz C, Dörner S, Trottmann F, Hertweck C, Sherwood A, Hoffmeister D. Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines. Chembiochem. 2022 Jul 5;23(13):e202200183. doi: 10.1002/cbic.202200183.

Erritzoe D., Roseman L., Nour M. M., MacLean K., Kaelen M., Nutt D. J., et al. (2018). Effects of Psilocybin Therapy on Personality Structure. Acta Psychiatr. Scand. 138, 368–378. Epub 2018/06/21. 10.1111/acps.12904

Nan-Xi Li, Yi-Ru Hu, Wang-Ni Chen, Bin Zhang, Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis, Journal of Affective Disorders, Volume 296, 2022, Pages 26-34, ISSN 0165-0327, https://doi.org/10.1016/j.jad.2021.09.041.

Sousa TR, Rema J, Machado S, Novais F. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Curr Top Med Chem. 2022;22(15):1250-1260. doi: 10.2174/1568026621666211201145800.

de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021 Sep 10;12:724606. doi: 10.3389/fpsyt.2021.724606.

Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. 2021 May;26(4):1265-1270. doi: 10.1007/s40519-020-01000-8.

Bird CIV, Modlin NL, Rucker JJH. Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int Rev Psychiatry. 2021 May;33(3):229-249. doi: 10.1080/09540261.2021.1919062.

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411.

Lutkajtis A. Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands. Journal of Psychedelic Studies. 2021 Apr 14. https://doi.org/10.1556/2054.2021.00162. Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front Psychol. 2021 Mar 15;12:645246. doi: 10.3389/fpsyg.2021.645246.

Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. Int J Mol Sci. 2021 Jan 15;22(2):835. doi: 10.3390/ijms22020835.

Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. Psilocybinassisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Sep 24;27:100538. doi: 10.1016/j.eclinm.2020.100538.

Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Front Psychiatry. 2019 Sep 13;10:672. doi: 10.3389/fpsyt.2019.00672.

Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019 Jun;44(7):1328-1334. doi: 10.1038/s41386-019-0324-9.

Tomasetti C, Montemitro C, Fiengo ALC, Santone C, Orsolini L, Valchera A, Carano A, Pompili M, Serafini G, Perna G, Vellante F, Martinotti G, Giannantonio MD, Kim YK, Nicola MD, Bellomo A, Ventriglio A, Fornaro M, Berardis DD. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. Curr Pharm Des. 2019;25(4):381-387. doi: 10.2174/1381612825666190312102444.

Geiger HA, Wurst MG, Daniels RN. DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chem Neurosci. 2018 Oct 17;9(10):2438-2447. doi: 10.1021/acschemneuro.8b00186.

Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018 Jul;32(7):811-819. doi: 10.1177/0269881117748902.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x.

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017 Oct 13;7(1):13187. doi: 10.1038/s41598-017-13282-7.

Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016 Dec;30(12):1220-1229. doi: 10.1177/0269881116679368.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513.

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7.

Magic mushroom compound is a potential treatment for patients with major depression. Nurs Stand. 2016 Jun 8;30(41):15. doi: 10.7748/ns.30.41.15.s18. PMID: 27286599.

Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. Front Psychol. 2017 Jul 25;8:1238. doi: 10.3389/fpsyg.2017.01238.

Geert-Jörgensen E. Further observations regarding hallucinogenic treatment. Acta Psychiatr Scand Suppl. 1968;203:195-200. doi: 10.1111/j.1600-0447.1968.tb01990.x.

Clinical trials

"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer", ClinicalTrials.gov ID: NCT05947383 (Registered 07/07/2023)

"Does Psilocybin Require Psychedelic Effects to Treat Depression?", ClinicalTrials.gov ID: NCT05710237 (Registered 01/24/2023)

"Psilocybin-assisted Interpersonal Therapy for Depression", ClinicalTrials.gov ID: NCT05581797 (Registered 10/17/2022)

"PET Synaptogenesis After Psilocybin In DEpression Recovery (PET-SPIDER)" ClinicalTrials.gov ID: NCT05601648 (Registered 10/31/2022)

"Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain", ClinicalTrials.gov ID: NCT05506982 (Registered 08/16/2022)

"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease (PDP)", ClinicalTrials.gov ID: NCT04932434 (Registered 06/21/2021)

"Psilocybin in Co-occurring Major Depressive Disorder and Borderline Personality Disorder", ClinicalTrials.gov ID: NCT05399498 (Registered 06/01/2022)

"Microdosing Psychedelics to Improve Mood", ClinicalTrials.gov ID: NCT05259943 (Registered 03/02/2022)

"The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation" ClinicalTrials.gov ID: NCT05220410 (Registered 01/21/2022)

"Pilot RECAP Study in Healthy Volunteers (RECAP)" ClinicalTrials.gov ID: NCT04842045 (Registered 04/09/2021)

"Psilocybin for Psychological and Existential Distress in Palliative Care" ClinicalTrials.gov ID: NCT04754061 (Registered 02/15/2021)

"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder (PsiloMDDAUD)" ClinicalTrials.gov ID: NCT04620759. (Registered 11/03/2020)

"Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder" Clinical Trials.gov ID: NCT03554174 (Registered 06/05/2018)

"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors" ClinicalTrials.gov ID: NCT02950467 (Registered 10/27/2016)

Public forum postings and other sources

Anon. "For Depression and Social Anxiety: An Experience with Mushrooms (exp115755)". Erowid.org. Sep 25, 2021. Erowid.org/exp/115755

Lavasani. "Magic Mushrooms Helped Me Cope With Postpartum Depression" Good Housekeeping. Jun 10, 2021. https://www.goodhousekeeping.com/health/wellness/a35681767/magic-mushrooms-postpartum-depression/

Guss. "The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)". 2020. https://psyarxiv.com/u6v9y/

J. "My Cognition Improves Tremendously: An Experience with Mushrooms & Amphetamines (Adderall XR) (exp111984)". Erowid.org. Aug 11, 2018. erowid.org/exp/111984